Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Clinical trial NCT07244393 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07244393
- Sponsor
- Cellbion Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-01
- Primary completion
- 2029-04-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.